As of 2020, buffering agents were the most prevalent excipient category in biotech-derived drugs. Biological drugs are less stable than small molecule drugs. Therefore, they need specific excipients, responsible for keeping the drug stable during the manufacturing process and storage.
Prevalence of excipient categories in biotech-derived drugs as of 2020
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
NCBI. (September 24, 2020). Prevalence of excipient categories in biotech-derived drugs as of 2020 [Graph]. In Statista. Retrieved December 22, 2024, from https://www.statista.com/statistics/1497274/prevalence-of-excipient-categories-in-biotech-drugs/
NCBI. "Prevalence of excipient categories in biotech-derived drugs as of 2020." Chart. September 24, 2020. Statista. Accessed December 22, 2024. https://www.statista.com/statistics/1497274/prevalence-of-excipient-categories-in-biotech-drugs/
NCBI. (2020). Prevalence of excipient categories in biotech-derived drugs as of 2020. Statista. Statista Inc.. Accessed: December 22, 2024. https://www.statista.com/statistics/1497274/prevalence-of-excipient-categories-in-biotech-drugs/
NCBI. "Prevalence of Excipient Categories in Biotech-derived Drugs as of 2020." Statista, Statista Inc., 24 Sep 2020, https://www.statista.com/statistics/1497274/prevalence-of-excipient-categories-in-biotech-drugs/
NCBI, Prevalence of excipient categories in biotech-derived drugs as of 2020 Statista, https://www.statista.com/statistics/1497274/prevalence-of-excipient-categories-in-biotech-drugs/ (last visited December 22, 2024)
Prevalence of excipient categories in biotech-derived drugs as of 2020 [Graph], NCBI, September 24, 2020. [Online]. Available: https://www.statista.com/statistics/1497274/prevalence-of-excipient-categories-in-biotech-drugs/